[HTML][HTML] BAFF is increased in renal transplant patients following treatment with alemtuzumab
Alemtuzumab is a monoclonal antibody that depletes T and B cells and is used as induction
therapy for renal transplant recipients. Without long-term calcineurin inhibitor (CNI) therapy,
alemtuzumab-treated patients have a propensity to develop alloantibody and may undergo
antibody-mediated rejection (AMR). In pursuit of a mechanistic explanation, we analyzed
peripheral B cells and serum of these patients for BAFF (Blys) and BAFF-R, factors known to
be integral for B-cell activation, survival, and homeostasis. Serum BAFF levels of 22/24 …
therapy for renal transplant recipients. Without long-term calcineurin inhibitor (CNI) therapy,
alemtuzumab-treated patients have a propensity to develop alloantibody and may undergo
antibody-mediated rejection (AMR). In pursuit of a mechanistic explanation, we analyzed
peripheral B cells and serum of these patients for BAFF (Blys) and BAFF-R, factors known to
be integral for B-cell activation, survival, and homeostasis. Serum BAFF levels of 22/24 …
